^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    AiRuiLi (adebrelimab)

    i
    Other names: SHR1316, SHR-1316, SHR 1316, HTI-1088, HTI-1316, HTI1088, HTI 1088, HTI 1316, HTI1316
    Associations

    News

    Trials
    Company:
    Jiangsu Hengrui Pharma
    Drug class:
    PD-L1 inhibitor
    Related drugs:
    Associations

    News

    Trials
    1d
    Liposomal Irinotecan, 5-fluorouracil/Calcium Folinate, Oxaliplatin, and Adebrelimab in Combination With Radiotherapy for Resectable or Borderline Resectable Pancreatic Cancer With Risk Factors：A Prospective Exploratory Study (clinicaltrials.gov)
    P2, N=37, Recruiting, Ningbo Medical Center Lihuili Hospital
    New P2 trial • IO biomarker
    |
    5-fluorouracil • oxaliplatin • leucovorin calcium • AiRuiLi (adebrelimab)
    2d
    SHR-A1811-II-203: A Trial of Injectable SHR-A1811 in Combination With Pyrotinib or SHR-1316 in Subjects With Advanced Non-small Cell Lung Cancer (clinicaltrials.gov)
    P1/2, N=324, Recruiting, Jiangsu HengRui Medicine Co., Ltd. | Trial completion date: Dec 2024 --> Dec 2026 | Trial primary completion date: Nov 2023 --> Dec 2026
    Trial completion date • Trial primary completion date
    |
    Irene (pyrotinib) • trastuzumab rezetecan (SHR-A1811) • AiRuiLi (adebrelimab)
    8d
    Efficacy and Safety of Adebrelimab Combined With Chemoradiotherapy in Patients With Unresectable Locally Advanced or Postoperative Recurrent Esophageal Squamous Cell Carcinoma (clinicaltrials.gov)
    P2, N=30, Recruiting, Nanfang Hospital, Southern Medical University | Trial completion date: Nov 2025 --> Nov 2026 | Trial primary completion date: Nov 2025 --> Nov 2026
    Trial completion date • Trial primary completion date
    |
    PD-L1 (Programmed death ligand 1)
    |
    cisplatin • paclitaxel • AiRuiLi (adebrelimab)
    9d
    Clinical Study of Adebrelimab Therapy in the Perioperative Treatment of Gastric Cancer or Gastroesophageal Junction Cancer (clinicaltrials.gov)
    P3, N=874, Not yet recruiting, Shanghai Shengdi Pharmaceutical Co., Ltd
    New P3 trial
    |
    oxaliplatin • Teysuno (gimeracil/oteracil/tegafur) • AiRuiLi (adebrelimab)
    14d
    SHR-A1921-205: Clinical Study of SHR-A1921 Combined With Adebrelimab and SHR-8068 With or Without Carboplatin in the Treatment of Advanced NSCLC (clinicaltrials.gov)
    P1/2, N=0, Withdrawn, Suzhou Suncadia Biopharmaceuticals Co., Ltd. | N=124 --> 0 | Not yet recruiting --> Withdrawn
    Enrollment change • Trial withdrawal
    |
    carboplatin • CS1002 (ipilimumab biosimilar) • AiRuiLi (adebrelimab) • tizetatug rezetecan (SHR-A1921)
    23d
    HAIBrave-001: HAI or IV of Adebrelimab, Combined With Bevacizumab and HAI of FOLFOX for Advanced Unresectable Hepatocellular Carcinoma (NCT06737913)
    P2, N=76, Recruiting, Sun Yat-sen University | Trial completion date: Dec 2027 --> Dec 2028 | Trial primary completion date: Dec 2027 --> Jun 2028
    Trial completion date • Trial primary completion date
    |
    Avastin (bevacizumab) • 5-fluorouracil • oxaliplatin • leucovorin calcium • AiRuiLi (adebrelimab)
    1m
    Neoadjuvant Adebrelimab Plus CRT for Locally Advanced Thymic Carcinoma (clinicaltrials.gov)
    P2, N=31, Not yet recruiting, Shanghai Chest Hospital
    New P2 trial
    |
    cisplatin • albumin-bound paclitaxel • AiRuiLi (adebrelimab)
    1m
    Study of Multi-mode Thermal Therapy Combined With Immunotherapy In Patients With HER2-negative Breast Cancer With Liver Metastases (clinicaltrials.gov)
    P2, N=30, Not yet recruiting, Fudan University
    New P2 trial
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 negative
    |
    Keytruda (pembrolizumab) • trastuzumab rezetecan (SHR-A1811) • Jiataile (sacituzumab tirumotecan) • AiRuiLi (adebrelimab)
    1m
    DAWN trial: a prospective, multicenter, single-arm phase II study of neoadjuvant disitamab vedotin (RC48) in combination with adebrelimab, apatinib, and S-1 for locally advanced HER2-positive gastric cancer. (PubMed, J Gastrointest Oncol)
    We hypothesize that the combination of these four therapeutic strategies could significantly enhance treatment efficacy in HER2-positive gastric cancer, particularly in combined positive score (CPS) PD-L1-negative patients. This study was registered at ClinicalTrials.gov (Identifier: NCT06385873).
    P2 data • Journal • PD(L)-1 Biomarker • IO biomarker
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    PD-L1 expression • HER-2 positive • HER-2 expression • PD-L1 negative • EGFR positive
    |
    AiTan (rivoceranib) • Aidixi (disitamab vedotin) • AiRuiLi (adebrelimab)
    1m
    A Phase III Study of HS-20093 Injection Combined With Adebrelimab Versus Docetaxel in Previously Treated Patients With Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer Without Actionable Genomic Alterations (clinicaltrials.gov)
    P3, N=450, Not yet recruiting, Hansoh BioMedical R&D Company
    New P3 trial
    |
    docetaxel • AiRuiLi (adebrelimab) • risvutatug rezetecan (GSK5764227)
    1m
    A Study Testing Emactinib Sulfate With Chemotherapy and Immunotherapy Before Surgery for Advanced Head and Neck Cancer (clinicaltrials.gov)
    P2, N=76, Recruiting, Second Affiliated Hospital, School of Medicine, Zhejiang University
    New P2 trial
    |
    CD8 (cluster of differentiation 8) • PD-1 (Programmed cell death 1) • HAVCR2 (Hepatitis A Virus Cellular Receptor 2)
    |
    cisplatin • albumin-bound paclitaxel • AiRuiLi (adebrelimab)
    2ms
    A Randomized, Double-blind, Placebo-controlled, Multicenter Phase II/III Clinical Study of Adebrelimab in Combination With SHR-8068 and Chemoradiotherapy as Perioperative Therapy for Locally Advanced Rectal Cancer (clinicaltrials.gov)
    P2/3, N=165, Not yet recruiting, Suzhou Suncadia Biopharmaceuticals Co., Ltd.
    New P2/3 trial
    |
    CS1002 (ipilimumab biosimilar) • AiRuiLi (adebrelimab)